SAFC and Novozymes have agreed to a 10-year extension of their world wide exclusive distribution agreement for Novozymes' Long R3 IGF-I growth factor. Long R3 is an alternative to insulin in cell culture that is currently used by several major producers of licensed biopharmaceuticals. It offers customers benefits ranging from supply risk mitigation, increased cell density and extended culture duration, and reduced manufacturing variability. The agreement enhances SAFC's leading market position as a critical raw material supplier to the biopharm and vaccine markets.
Posted by Bruce Lehr August 17th 2010.
Comments